{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-274124","form_type":"8-K","ticker":"ACRV","cik":"0001781174","company_name":"Acrivon Therapeutics, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.398325+00:00","generated_at":"2026-06-08T07:16:45.750203+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Acrivon Q3 net loss $14.5M; cash $142.1M; ACR-368 shows early clinical activity","bullets":["Net loss of $14.5M in Q3 2023 vs $9.2M in Q3 2022; R&D expenses $10.3M, G&A $5.9M.","Cash and marketable securities $142.1M as of Sept 30, 2023; expected to fund operations into H2 2025.","ACR-368: initial clinical activity observed in OncoSignature-positive patients across ovarian, endometrial, urothelial cancers; mature data H1 2024.","ACR-2316 dual WEE1/PKMYT1 inhibitor: IND submission planned Q4 2024; designed for superior single-agent activity via AP3 platform.","Two posters at AACR-NCI-EORTC conference validate ACR-368 OncoSignature assay with 47-58% ORR in tumor biopsies."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-274124","json":"https://secwatch.observer/filing/0001193125-23-274124.json","markdown":"https://secwatch.observer/filing/0001193125-23-274124.md","text":"https://secwatch.observer/filing/0001193125-23-274124.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781174/000119312523274124/0001193125-23-274124-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781174/000119312523274124/d591379d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:16:45.750203+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d51213b67bde7ccf21ca0b58bd43f39e5f35b0aa","claim":"Acrivon Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: net income $14.5 million.","evidence_excerpt":"Net loss for the quarter ended September 30, 2023 was $14.5 million compared to a net loss of $9.2 million for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781174/000119312523274124/0001193125-23-274124-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Net income","value":"$14.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}